Why BPC-157 sits outside the pharmacy
A peptide with a huge online following has no approved product, a regulator flag for compounding and a place on the anti-doping list. Here is how each of those came about.
What's new
A status check on one of the most searched unapproved peptides: what regulators and sport authorities have actually said.
Why it matters
Online sellers often blur the line between "research chemical" and medicine. The regulatory record is clearer than the marketing.
What's next
Any change to FDA's compounding lists or new human trial results would be news; we will report either.
BPC-157 is a 15-amino-acid peptide derived from a protein found in stomach juice. It is promoted online for tendon, gut and injury healing. Here is where it stands with the bodies that decide what can be sold as a medicine or used in sport.
No approved product
No medicine containing BPC-157 is approved by the FDA or the European Medicines Agency. Most published evidence comes from animal studies; well-controlled human trials are scarce.
A compounding flag
In 2023 the FDA placed BPC-157 in a category of bulk substances that raise significant safety concerns, which means US pharmacies should not use it to compound medicines. The agency cited limited human safety data and potential risks including immune reactions and impurities.
Banned in sport
The World Anti-Doping Agency lists BPC-157 under S0, "non-approved substances", which are prohibited at all times for athletes.
The "research use only" label
Vials sold online are often labelled "not for human consumption". That label is a legal workaround, not a quality standard. Independent tests of grey-market peptides have repeatedly found wrong amounts, impurities or contamination.
| Body | Status |
|---|---|
| FDA (approval) | None |
| FDA (compounding) | Flagged for safety concerns |
| EMA | None |
| WADA | Prohibited (S0) |
Popularity is not evidence, and a label saying "research only" is not a safety check.
